Business Context and Reporting Period
Company: Cardinal Health, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended December 31, 1997 (Fiscal Year 1998).
Business Overview: The Company operates primarily in wholesale distribution of pharmaceuticals (91% of revenues) and healthcare services including pharmacy automation and management.
Key Financial Metrics
| Metric (in thousands) | Q2 1997 | Q2 1996 | 6 Months 1997 | 6 Months 1996 |
|---|---|---|---|---|
| Net Revenues | $3,130,505 | $2,816,406 | $6,000,476 | $5,351,882 |
| Gross Margin | $248,898 | $223,858 | $474,763 | $417,686 |
| Operating Earnings | $110,498 | $78,429 | $199,126 | $147,943 |
| Net Earnings | $66,179 | $41,326 | $120,218 | $80,652 |
| Diluted EPS | $0.60 | $0.38 | $1.08 | $0.75 |
| Cash and Equivalents | $111,654 | $87,460 | $111,654 | $87,460 |
| Working Capital | $1,185,230 | N/A | $1,185,230 | N/A |
Note: Working Capital calculated as Total Current Assets ($2,954,558) minus Total Current Liabilities ($1,769,328) as of Dec 31, 1997.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 11% for the quarter and 12% for the six-month period compared to the prior year. Approximately 80% of this growth was driven by existing customers through increased volume and price increases.
- Profitability: Net earnings rose significantly, up 60% for the quarter and 49% for the six-month period. Operating earnings increased 41% for the quarter.
- Margins: Gross margin percentage remained stable at 7.95% for the quarter. However, the Distribution business margin decreased slightly to 5.40% due to competitive market pressures and a higher mix of high-volume customers.
- Merger Costs: Merger-related costs decreased substantially to $3.2 million for the quarter (down from $18.0 million in the prior year), reflecting the completion of major integration activities from the previous fiscal year.
- Liquidity: Cash and equivalents decreased by $131 million during the six-month period, primarily due to increased inventory purchases ($502 million) and trade receivables ($86 million) to support business growth.
Guidance, Outlook, and Risks
Pending Mergers and Integration
- MediQual Systems: A stock-for-stock merger is expected to close in Q1 1998. Estimated transaction costs are $4 million.
- Bergen Brunswig: A major stock-for-stock merger is expected to close in Q1 1998. Cardinal will issue approximately 41 million shares and assume $646 million in long-term debt. Estimated merger-related charges are between $100 million and $130 million (after tax).
- Future Costs: The Company estimates an additional $6.3 million in merger integration costs for completed deals in fiscal 1998.
Year 2000 Compliance
The Company estimates $20 million in costs to remediate Year 2000 issues, expecting completion by the end of calendar 1998. While management believes this will not materially impact financial statements, there is a risk that third-party failures could adversely affect operations.
Legal Proceedings
The Company is a defendant in the "Brand Name Prescription Drug Litigation." A summary judgment previously granted in the Company's favor was reversed by the Court of Appeals in August 1997. The Company has petitioned the Supreme Court for review. Trial is set for September 1998. Management believes the allegations are without merit and does not anticipate a material adverse effect.
Accounting Changes
Beginning with the fiscal year ending June 30, 1998, the Company will report bulk deliveries to customer warehouses as revenues rather than excluding them, following industry guidance.
Investor Verification Checklist
- Bergen Brunswig Merger Approval: Verify shareholder and regulatory approvals for the Bergen merger scheduled for February 20, 1998, given the significant debt assumption ($646M) and estimated charges ($100M-$130M).
- Antitrust Litigation Status: Monitor the Supreme Court petition regarding the Brand Name Prescription Drug Litigation and the scheduled September 1998 trial.
- Year 2000 Remediation: Confirm the timeline and budget adherence for the $20 million Y2K project and assess third-party vendor compliance.
- Revenue Recognition Policy: Review the upcoming change in revenue recognition for bulk deliveries in the next fiscal year to understand its impact on reported top-line growth.
- Debt Service Capacity: Assess the Company's ability to service the additional $646 million in debt from the Bergen merger alongside existing obligations.